NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 239 filers reported holding NEKTAR THERAPEUTICS in Q2 2021. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $515,000 | +56.5% | 28,689 | +49.4% | 0.01% | +40.0% |
| Q2 2021 | $329,000 | -15.4% | 19,198 | -1.2% | 0.01% | -28.6% |
| Q1 2021 | $389,000 | +15.1% | 19,429 | -2.4% | 0.01% | +16.7% |
| Q4 2020 | $338,000 | -52.7% | 19,904 | -53.8% | 0.01% | -60.0% |
| Q3 2020 | $715,000 | -44.5% | 43,079 | -27.9% | 0.02% | -74.1% |
| Q4 2019 | $1,289,000 | +119.2% | 59,737 | +85.1% | 0.06% | +346.2% |
| Q3 2019 | $588,000 | -25.3% | 32,268 | +46.0% | 0.01% | -31.6% |
| Q2 2019 | $787,000 | +51.1% | 22,107 | +42.7% | 0.02% | +35.7% |
| Q1 2019 | $521,000 | -41.1% | 15,494 | -42.4% | 0.01% | -54.8% |
| Q4 2018 | $884,000 | -37.9% | 26,891 | +15.2% | 0.03% | -42.6% |
| Q3 2018 | $1,424,000 | +294.5% | 23,352 | +215.9% | 0.05% | +237.5% |
| Q2 2018 | $361,000 | -44.8% | 7,393 | +20.2% | 0.02% | -55.6% |
| Q1 2018 | $654,000 | – | 6,153 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |